1. Home
  2. LGO vs CRDF Comparison

LGO vs CRDF Comparison

Compare LGO & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Largo Inc.

LGO

Largo Inc.

HOLD

Current Price

$0.73

Market Cap

73.7M

Sector

N/A

ML Signal

HOLD

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

HOLD

Current Price

$1.33

Market Cap

86.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LGO
CRDF
Founded
1988
1999
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
73.7M
86.8M
IPO Year
2007
2012

Fundamental Metrics

Financial Performance
Metric
LGO
CRDF
Price
$0.73
$1.33
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$3.25
$9.63
AVG Volume (30 Days)
2.1M
1.3M
Earning Date
05-12-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
27.37
EPS
N/A
N/A
Revenue
N/A
$365,993.00
Revenue This Year
$50.56
N/A
Revenue Next Year
$59.94
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
49.61
52 Week Low
$0.62
$1.16
52 Week High
$2.70
$4.56

Technical Indicators

Market Signals
Indicator
LGO
CRDF
Relative Strength Index (RSI) 43.85 46.17
Support Level $0.62 $1.18
Resistance Level $0.85 $1.66
Average True Range (ATR) 0.07 0.10
MACD 0.02 0.02
Stochastic Oscillator 42.78 52.17

Price Performance

Historical Comparison
LGO
CRDF

About LGO Largo Inc.

Largo Inc is committed to the production and supply of high-quality vanadium products. The company is also focused on the advancement of renewable energy storage solutions through Largo Clean Energy and its vanadium redox flow battery technology. The Company is engaged in the mining, exploration, and development of mineral properties, predominantly in Brazil, through which it produces and supplies vanadium products VPURE Flake, VPURE+ Flake, and VPURE+ Powder. The company has operating segments: sales & trading, mine properties, which generates key revenue, corporate, exploration and evaluation properties, Clean Energy, and Largo Physical Vanadium.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.

Share on Social Networks: